Start of operation of the updated EudraVigilance system – an information system established and maintained by the European Medicines Agency (EMA) for collection of adverse drug reaction reports regarding medicines authorised and used in clinical research in all EEA countries.
For the second time the Agency implements a social media campaign simultaneously with other EEA countries to promote reporting of adverse drug reactions. In 2017, campaign activities are mostly aimed at reporting adverse drug reactions caused by non prescription medicines.
1) Additional parameter “Disease group (by ATC)” allows searching for medicines intended for a specific disease group; 2) Added functionality that allows ordering selected list of medicines according to maximum price allowed in pharmacies.
As part of the Joint audit program (JAP) of the European Union member states, European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA) conducted a joint audit (inspection) of the compliance of processes organized and practical activities performed by the Agency with the international requirements in the field of compliance evaluation of good manufacturing practice and good distribution practice.
In March and April 2017, Agency implemented a public information campaign “How not to overpay for medicines?” in collaboration with the society Health Projects for Latvia. As part of the campaign, an informative bulletin “RATIONAL CHOICE OF MEDICINES” was prepared for doctors .